Featured Publications from Ludwig Investigators
Featured Publications
2026
Lee, Y. S. et al. Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia. Blood neoplasia 3, 100202 (2026).
Lee, Y. S. et al. Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia. Blood neoplasia 3, 100202 (2026).
Wu, B. et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for immunotherapy of cancer 14, (2026).
Wu, B. et al. TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. Journal for immunotherapy of cancer 14, (2026).
Goyette, M.-A. et al. HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. Cancer discovery (2026) doi:10.1158/2159-8290.CD-25-1459.
Goyette, M.-A. et al. HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. Cancer discovery (2026) doi:10.1158/2159-8290.CD-25-1459.
Lee, S. M. et al. Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation. Cell reports 45, 117160 (2026).
Lee, S. M. et al. Host microRNA-31-5p regulates KHDRBS3 expression and modulates viral gene expression during KSHV lytic reactivation. Cell reports 45, 117160 (2026).
Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287–1304.e18 (2026).
Meylan, M. et al. Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. Cell 189, 1287–1304.e18 (2026).